Declan Fallon
fallond
I am a self-confessed Blogger, Market Technician for ActivateClients.com, and Community Director of Zignals.com. Follow me on Twitter and Stocktwits @fallondpicks
Recent Articles by Declan Fallon
Nov 29, 2013
by Declan Fallon
Is There More to Isis Pharmaceuticals Than Kynamro?
The year started with a bang for Isis Pharmaceuticals with the first antisense treatment approved by the FDA in nearly 15 years. But since then, things have gone quiet -- but its stock is still climbing -- are investors right to buy?
Nov 22, 2013
by Declan Fallon
Opportunities in Lung Cancer Therapies
The market for lung cancer therapies is expected to reach $7 billion in 2019, but the successful treatment of lung cancer involves a complex relationship of genetic relationships. What companies are leading the charge to decode these relationships?
Nov 9, 2013
by Declan Fallon
Is This Cubist's Biggest Opportunity?
The war on microbes has an important ally. Cubist Pharmaceuticals (Nasdaq: CBST) has a $1 billion antibiotic franchise and is getting ready to launch another. It also has partnerships with big pharmas AstraZeneca (NYSE: AZN) and Novartis (NYSE: NVS).
Oct 15, 2013
by Declan Fallon
The Fight for the Hypercholesterolemia Market
Three companies are fighting it out for the homozygous familial hypercholesterolemia market, while one is aiming at the heterozygous familial hypercholesterolemia. As a rare disease, the payoff can be high, so who will win the race for the largest market share?
Oct 7, 2013
by Declan Fallon
Array BioPharma Needs a Partner to Take It to the Next Level
Array BioPharma is aiming to break in to the highly lucrative asthma market with its development treatment, ARRY-502. The only problem is it hasn't secured a partner to help develop the treatment into a commercial drug.
Sep 27, 2013
by Declan Fallon
A Reshuffle in a $27 Billion Market
GlaxoSmithKline's Advair controls the largest portion of the asthma and COPD market, but it will soon find itself facing competition from another products, including one from its own stable. How will things shape out for this $27 billion market in the next couple of years?
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.